Table 3.
Results of SPG stimulation on pain intensity, as measured by the Visual Analog Scale (VAS), and overall health status, assessed using the SF-36, were evaluated after 2 weeks of trial stimulation at 6 and 12 months post-implantation.
| Patient | Preoperative VAS | Preoperative SF-36 | VAS 2 weeks | SF-36 2 weeks | VAS 6 months | SF-36 6 months | VAS 12 months | SF-36 12 months |
|---|---|---|---|---|---|---|---|---|
| JAW | 8 | 50 | 4 | 60 | 3 | 80 | 3 | 80 |
| EB | 9 | 50 | 3 | 70 | 2 | 80 | 2 | 80 |
| KW | 9 | 60 | 4 | 70 | 3 | 80 | 2 | 80 |
| MM | 10 | 30 | 3 | 70 | — | — | — | — |
| SC | 8 | 50 | 4 | 80 | 4 | 80 | 2 | 80 |
| WP | 10 | 60 | 4 | 70 | — | — | — | — |
| Mean | 9 | 50 | 3.6 | 70 | 3 | 80 | 2.25 | 80 |
All patients experienced at least a 50% reduction in pain intensity after the trial period. Consequently, all patients proceeded with the implantation of a non-rechargeable implantable pulse generator (IPG) in the supraclavicular region on the ipsilateral side.